Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Xabier Mielgo Rubio"'
Autor:
Abrahams Ocanto, Xabier Mielgo-Rubio, Javier Luna Tirado, Nuria Linares Mesa, Marta López Valcárcel, Sara Pedraza, Victoria Vera Barragan, Patricia Valencia Nieto, Juan Zafra Martín, Felipe Couñago
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 4, Iss 5, Pp 1082-1094 (2023)
Oncology patients are more susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection due to hospital contact and an immunological system that can be compromised by antineoplastic therapy and supportive treatments. Certain
Externí odkaz:
https://doaj.org/article/66faa5f2312e4280a62d0301cbe9d5ce
Publikováno v:
World Journal of Clinical Oncology. 13:758-761
Recent data from a phase 3 trial have shown that the addition of immunotherapy to neoadjuvant chemotherapy improves event-free survival in patients with non-small-cell lung cancer (NSCLC). This is the first positive phase 3 trial in this setting, alt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::807cf68260303787ea7019c259fd8f3a
https://doi.org/10.5306/wjco.v13.i9.758
https://doi.org/10.5306/wjco.v13.i9.758
Autor:
Rafael López-Castro, Tania García-Peña, Xabier Mielgo-Rubio, Mariona Riudavets, Cristina Teixidó, Noelia Vilariño, Felipe Couñago, Laura Mezquita
Publikováno v:
Personalized Medicine. 19:341-359
In recent years, major advances have been achieved in our understanding of non-small-cell lung cancer (NSCLC) with oncogenic driver alterations and in the specific treatment of these with tyrosine kinase inhibitors. Currently, state-of-the-art manage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd64a6078815e3e8b7e5f0e878170809
https://doi.org/10.2217/pme-2021-0059
https://doi.org/10.2217/pme-2021-0059
Autor:
María Sereno, Luis Cabezón-Gutiérrez, Oliver Higuera, Xabier Mielgo-Rubio, Raquel Cervera-Calero
Publikováno v:
Future Oncology.
Aim: To define high tumor burden (HTB) in non-small-cell lung cancer. Methods: A total of five oncologists initiated the project, selecting 66 participants, and elaborated a questionnaire with 26 statements using the Delphi method with a 9-point Like
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::968783be775fd33ce9358f9f2a33f4b4
https://doi.org/10.2217/fon-2022-1016
https://doi.org/10.2217/fon-2022-1016
Autor:
Maria Eugenia Olmedo, Raquel Cervera, Luis Cabezon-Gutierrez, Yolanda Lage, Elena Corral de la Fuente, Ana Gómez Rueda, Xabier Mielgo-Rubio, Juan Carlos Trujillo, Felipe Couñago
Publikováno v:
World Journal of Clinical Oncology. 13:276-286
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fb8920aab38a839e85bd31a4af3a9e2
https://doi.org/10.5306/wjco.v13.i4.276
https://doi.org/10.5306/wjco.v13.i4.276
Autor:
Javier Serrano, Ana Alvarez Gonzalez, B. Taboada, Juan Carlos Trujillo Reyes, Xabier Mielgo-Rubio, Patricia Calvo Crespo, Antonio Gómez Caamaño, R. Garcia, Felipe Couñago
Publikováno v:
World Journal of Clinical Oncology
This manuscript collects in a joint and orderly manner the existing evidence at the present time about postoperative treatment with radiotherapy in non-small cell lung cancer. It also systematically reviews the current evidence, the international rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56ff117b1fb4b489ff6c5b6a71eb906e
https://doi.org/10.5306/wjco.v12.i10.833
https://doi.org/10.5306/wjco.v12.i10.833
Autor:
Felipe Couñago, Carlos Carracedo, Cesar Torres-Mattos, María Ángeles González-Ruiz, Xabier Mielgo-Rubio, Miguel J Sotelo, Juan Carlos Trujillo-Reyes, Héctor Milián, José Luis García
Publikováno v:
World Journal of Clinical Oncology
Patients with early-stage non-small-cell lung cancer (NSCLC) are candidates for curative surgery; however, despite multiple advances in lung cancer management, recurrence rates remain high. Adjuvant chemotherapy has been demonstrated to significantly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86da448314708fbbb624e6d29a3489d7
https://doi.org/10.5306/wjco.v12.i10.912
https://doi.org/10.5306/wjco.v12.i10.912
Autor:
Amir Shabaka, Gema Fernández-Juárez, Xabier Mielgo-Rubio, Sara Gimenez-Moyano, Carmen Guerrero-Marquez, Paula Martinez de la Cruz
Publikováno v:
The American Journal of the Medical Sciences. 362:99-102
Tipifarnib is a novel targeted treatment for hematologic malignancies that is being recently studied for the treatment of advanced solid organ tumors with HRAS mutations. There have been scarce reports on kidney adverse events in initial phase I and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f2ec028daa930df09117b9ab3960a77
https://doi.org/10.1016/j.amjms.2021.04.003
https://doi.org/10.1016/j.amjms.2021.04.003
Autor:
Javier, Garde-Noguera, Margarita, Martín-Martín, Andres, Obeso, Miriam, López-Mata, Inigo Royo, Crespo, Lira, Pelari-Mici, O, Juan Vidal, Xabier, Mielgo-Rubio, Juan Carlos, Trujillo-Reyes, Felipe, Couñago
Publikováno v:
Scientia
Non-small cell lung cancer; Oligometastatic Cáncer de pulmón de células no pequeñas; Oligometastásico Càncer de pulmó de cèl·lules no petites; Oligometastàtic The management of patients with advanced non-small cell lung carcinoma (NSCLC) ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d27fc45c02a936d7f54bb6dee73337c
https://hdl.handle.net/11351/8662
https://hdl.handle.net/11351/8662
Autor:
Luis, Cabezón-Gutiérrez, María, Sereno, Raquel, Cervera-Calero, Xabier, Mielgo-Rubio, Oliver, Higuera
Publikováno v:
Journal of clinical and translational research. 8(5)
Lung cancer is the leading cause of cancer death worldwide and the majority of the patients have advanced/metastatic disease on presentation. In clinical practice, several biomarkers and clinical factors are taken into account when choosing the best
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::eb817e0b4a62fdefc1e36bd75f38675c
https://pubmed.ncbi.nlm.nih.gov/36518549
https://pubmed.ncbi.nlm.nih.gov/36518549